1052271-60-9 Usage
General Description
8-bromoimidazo[1,5-a]pyridine is a heterocyclic compound that consists of an imidazo[1,5-a]pyridine core with a bromine atom at the 8-position. It is commonly used in the field of organic and medicinal chemistry as a building block for the synthesis of various biologically active molecules. 8-bromoimidazo[1,5-a]pyridine has shown potential as a pharmaceutical intermediate and has been studied for its potential applications in drug development. It exhibits interesting chemical reactivity and has been utilized in the development of small molecule inhibitors for various biological targets. Additionally, 8-bromoimidazo[1,5-a]pyridine has been investigated for its potential use in materials science, including the development of novel organic semiconductor materials. Overall, this chemical compound has shown promise for a wide range of applications in the scientific and industrial sectors.
Check Digit Verification of cas no
The CAS Registry Mumber 1052271-60-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,2,2,7 and 1 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1052271-60:
(9*1)+(8*0)+(7*5)+(6*2)+(5*2)+(4*7)+(3*1)+(2*6)+(1*0)=109
109 % 10 = 9
So 1052271-60-9 is a valid CAS Registry Number.
1052271-60-9Relevant articles and documents
POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
-
Page/Page column 299, (2021/06/11)
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
